$25.09
0[0.00%]
At close: Apr 24
$25.09
0[0.00%]
PreMarket: 4:20PM EDT
Avidity Biosciences
(NASDAQ:RNA)Avidity Biosciences Stock (NASDAQ:RNA), Analyst Ratings, Price Targets, Predictions
Avidity Biosciences Inc has a consensus price target of $41.9, established from looking at the 38 latest analyst ratings. The last 3 analyst ratings were released from Needham, Cantor Fitzgerald, and Chardan Capital on April 11, 2024, March 14, 2024, and March 5, 2024. With an average price target of $42.67 between Needham, Cantor Fitzgerald, and Chardan Capital, there's an implied 70.05% upside for Avidity Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Cantor Fitzgerald
Chardan Capital
Wells Fargo
Credit Suisse
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Avidity Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | 139.14% | Cantor Fitzgerald | Eric Schmidt | → $60 | Initiates | → Overweight | Get Alert |
| 03/05/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | 31.53% | Chardan Capital | Keay Nakae | $23 → $33 | Maintains | Buy | Get Alert |
| 03/04/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | -8.33% | Chardan Capital | Keay Nakae | → $23 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | RNA | Buy Now | Avidity Biosciences | $25.09 | 99.28% | Wells Fargo | Yanan Zhu | $50 → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 11/29/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 19.57% | Credit Suisse | Judah Frommer | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | -8.33% | Chardan Capital | Keay Nakae | $27 → $23 | Maintains | Buy | Get Alert |
| 08/09/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | -20.29% | Evercore ISI Group | Josh Schimmer | → $20 | Upgrade | In-Line → Outperform | Get Alert |
| 05/17/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 99.28% | Wells Fargo | Yanan Zhu | $55 → $50 | Maintains | Overweight | Get Alert |
| 05/10/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 19.57% | Credit Suisse | Judah Frommer | → $30 | Reiterates | → Outperform | Get Alert |
| 04/28/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 39.5% | Needham | Joseph Stringer | → $35 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 19.57% | Credit Suisse | Judah Frommer | $35 → $30 | Maintains | Outperform | Get Alert |
| 03/31/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | -20.29% | Evercore ISI Group | Joshua Schimmer | → $20 | Downgrade | Outperform → In-Line | Get Alert |
| 03/31/2023 | RNA | Buy Now | Avidity Biosciences | $25.09 | 7.61% | Chardan Capital | Keay Nakae | → $27 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Avidity Biosciences (RNA)?
The latest price target for Avidity Biosciences (NASDAQ: RNA) was reported by Needham on April 11, 2024. The analyst firm set a price target for $35.00 expecting RNA to rise to within 12 months (a possible 39.50% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avidity Biosciences (RNA)?
The latest analyst rating for Avidity Biosciences (NASDAQ: RNA) was provided by Needham, and Avidity Biosciences reiterated their buy rating.
When was the last upgrade for Avidity Biosciences (RNA)?
The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.
When was the last downgrade for Avidity Biosciences (RNA)?
The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.
When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Avidity Biosciences (RNA) correct?
While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a reiterated with a price target of $0.00 to $35.00. The current price Avidity Biosciences (RNA) is trading at is $25.09, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.